160 related articles for article (PubMed ID: 11086205)
1. The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer.
Shepherd FA; Abratt R; Crino L; Green M; Sandler A; Steward W; Iglesias J; Anglin G
Lung Cancer; 2000 Nov; 30(2):117-25. PubMed ID: 11086205
[TBL] [Abstract][Full Text] [Related]
2. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
[TBL] [Abstract][Full Text] [Related]
3. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
[TBL] [Abstract][Full Text] [Related]
4. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group.
Comella P; Frasci G; Panza N; Manzione L; De Cataldis G; Cioffi R; Maiorino L; Micillo E; Lorusso V; Di Rienzo G; Filippelli G; Lamberti A; Natale M; Bilancia D; Nicolella G; Di Nota A; Comella G
J Clin Oncol; 2000 Apr; 18(7):1451-7. PubMed ID: 10735892
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
[TBL] [Abstract][Full Text] [Related]
7. A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer.
Sculier JP; Lafitte JJ; Lecomte J; Alexopoulos CG; Van Cutsem O; Giner V; Efremidis A; Berchier MC; Collon T; Meert AP; Scherpereel A; Ninane V; Paesmans M; Berghmans T;
Ann Oncol; 2007 Jun; 18(6):1037-42. PubMed ID: 17404152
[TBL] [Abstract][Full Text] [Related]
8. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.
Soto Parra H; Cavina R; Latteri F; Sala A; Dambrosio M; Antonelli G; Morenghi E; Alloisio M; Ravasi G; Santoro A
Ann Oncol; 2002 Jul; 13(7):1080-6. PubMed ID: 12176787
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.
Morabito A; Gebbia V; Di Maio M; Cinieri S; Viganò MG; Bianco R; Barbera S; Cavanna L; De Marinis F; Montesarchio V; Costanzo R; Sandomenico C; Montanino A; Mancuso G; Russo P; Nacci A; Giordano P; Daniele G; Piccirillo MC; Rocco G; Gridelli C; Gallo C; Perrone F
Lung Cancer; 2013 Jul; 81(1):77-83. PubMed ID: 23643177
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8.
Akcali Z; Calikusu Z; Sakalli H; Ozyilkan O
Tumori; 2008; 94(4):474-80. PubMed ID: 18822681
[TBL] [Abstract][Full Text] [Related]
11. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.
Castellano D; Lianes P; Paz-Ares L; Hidalgo M; Guerra JA; Gómez-Martín C; Gómez H; Calzas J; Cortés-Funes H
Ann Oncol; 1998 Apr; 9(4):457-9. PubMed ID: 9636840
[TBL] [Abstract][Full Text] [Related]
13. A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer.
Guarino MJ; Schneider CJ; Grubbs SS; Biggs DD; Himelstein AL; Hogaboom K; Tilak S
Oncologist; 2002; 7(6):509-15. PubMed ID: 12490738
[TBL] [Abstract][Full Text] [Related]
14. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
Stewart DJ; Tomiak E; Shamji FM; Maziak DE; MacLeod P
Lung Cancer; 2004 May; 44(2):241-9. PubMed ID: 15084389
[TBL] [Abstract][Full Text] [Related]
16. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
[TBL] [Abstract][Full Text] [Related]
17. Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone.
Novello S; Bruzzi P; Barone C; Buosi R; Masotti A; Michetti G; Fioretti M; Barbera S; Spatafora M; Garetto L; Mazzanti P; Dongiovanni V; Selvaggi G; Crinò L; Scagliotti GV
Ann Oncol; 2007 May; 18(5):903-8. PubMed ID: 17351253
[TBL] [Abstract][Full Text] [Related]
18. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Georgoulias V; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Palamidas P; Vlachonikolis I;
Lancet; 2001 May; 357(9267):1478-84. PubMed ID: 11377599
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.
Laack E; Dickgreber N; Müller T; Knuth A; Benk J; Lorenz C; Gieseler F; Dürk H; Engel-Riedel W; Dalhoff K; Kortsik C; Graeven U; Burk M; Dierlamm T; Welte T; Burkholder I; Edler L; Hossfeld DK;
J Clin Oncol; 2004 Jun; 22(12):2348-56. PubMed ID: 15197195
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]